AS
Alec Stranahan BofA Securities Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
13
Avg Return
Past Year
Past Year
4.2%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past 3 Months
Buy
16.7%
Hold
50%
Sell
33.3%
| Stock | Rating | Price Target |
Upside Downside |
Ratings 3 Months |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
Candel Therapeutics
CADL
$340M
|
Hold
Downgraded
| $7 |
13%
upside
| 1 | -25% |
0
%
| 3 Sep ‘25 1 month ago |
|
Xencor
XNCR
$929M
|
Hold
Downgraded
| $12 |
8%
downside
| 1 | – |
–
| 3 Sep ‘25 1 month ago |
|
Erasca
ERAS
$684M
|
Sell
Downgraded
| $1 |
59%
downside
| 1 | -45% |
0
%
| 3 Sep ‘25 1 month ago |
|
Novavax
NVAX
$1.35B
|
Sell
Downgraded
| $7 |
16%
downside
| 2 | +13% |
0
%
| 20 Aug ‘25 1 month ago |
|
Krystal Biotech
KRYS
$5.25B
|
Buy
Maintained
| $192 |
6%
upside
| 1 | +23% |
0
%
| 22 Jul ‘25 2 months ago |
|